Slide 1: Ipca Laboratories Ltd. Corporate Presentation
Ipca Laboratories Ltd. Corporate Presentation June 2022 1
Slide 2: Company Overview
Company Overview Incorporation : 1949 Present Management : Since 1975 Total income F. Y. 2021-22 : Rs. 5455.49 Crs / US$ 733 Mn (Standalone) Rs. 5896.36 Crs / US$ 792 Mn (Consolidated) Exports F. Y. 2021-22 : Rs. 2502.69 Crs / US$ 336 Mn Business Model : Integrated pharmaceutical company producing B
Slide 3: Five Years' Highlights - Standalone
Five Years’ Highlights Standalone 2017-18 2018-19 2019-20 2020-21 2021-22 Domestic Income ( Rs. Crs ) 1,694.54 1,956.90 2,288.37 2,484.21 2,952.80 Domestic Income (US $ Mn) 239.21 276.24 323.03 333.94 396.56 Export Income ( Rs. Crs ) 1,564.21 1,730.84 2,143.75 2,717.19 2,502.69 Export Income (US $ M
Slide 4: Five Years' Highlights - Consolidated
Five Years’ Highlights Consolidated 2017-18 2018-19 2019-20 2020-21 2021-22 Domestic Income ( Rs. Crs ) 1,694.68 1,956.90 2,327.88 2,519.77 3,077.75 Domestic Income (US $ Mn) 239.23 276.24 328.61 338.72 413.34 Export Income ( Rs. Crs ) 1,630.69 1,873.96 2,387.83 2,963.06 2,818.61 Export Income (US $
Slide 5: Manufacturing Facilities: Formulations
Manufacturing Facilities Formulations 5
Slide 6: Manufacturing Facilities - Formulations
Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections UK-MHRA, TGA-Australia, WHO-Geneva, EU Certification Athal by German Authority, Health Canada, GCC, MOH- (Dadra & Nagar Tablets & Capsules Columbia, FDA Ghana, MOH Oman, NDA - Uganda, NHRA Haveli) – Bahrain, Medicine
Slide 7: Manufacturing Facilities - Formulations
Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections Silvassa WHO-GMP, TGA-Australia, Health-Canada, Tablets & Capsules (Dadra & Nagar Haveli) Local FDA Unit – I : WHO-GMP Dehradun, Tablets & Unit - II: WHO-GMP, GHANA-FDA, (Uttarakhand) Cephalosporin Injectables NAFDAC
Slide 8: Manufacturing Facilities: Active Pharmaceutical Ingredients (APIs)
Manufacturing Facilities Active Pharmaceutical Ingredients (APIs) 8
Slide 9: Manufacturing Facilities - APIs
Manufacturing Facilities APIs Location Approvals / Inspections TGA-Australia, EDQM, PMDA-Japan, WHO-Geneva, Ratlam (Madhya Pradesh) Health Canada, EU-GMP (LaGesso, Berlin), MOH Russia, MFDS (Korea), CDSCO- India, Cofepris (Mexico), EU WC Indore (Madhya Pradesh) WHO-Geneva, CDSCO- India, EU WC Ankles
Slide 10: Revenue Break-up
S£ipca dose of life Revenue Break-up
Slide 11: Revenue Break-up - Standalone
Revenue Break-up - Standalone 2021 - 22 25% Formulations Domestic Total 46% Total Revenue 54% API Exports 75% 11% 59% Formulations Formulations Exports Domestic 41% API API 89% 11
Slide 12: Revenue Break-up Standalone
Revenue Break-up Standalone 2021-22 2020-21 Rs. Crs Domestic Exports Total Domestic Exports Total Growth Branded Formulations 2508.27 415.99 2924.26 1981.67 403.42 2385.09 22.6% Generic/ Institution/ Tender Formulations - 1070.75 1070.75 - 1193.77 1193.77 -10.3% Total Formulations 2508.27 1486.74 39
Slide 13: Financials
S£ipca dose of life Financials
Slide 14: Financials - Standalone
Financials - Standalone F.Y. 2021 - 22 F.Y. 2020 - 21 % Rs. Crs US$ Mn Rs. Crs US$ Mn Growth Total Income 5455.49 733 5201.40 699 5% EBIDT 1268.20 170 1534.47 206 -17% EBIDT % 23.25% 29.50% PBT # 1088.36 146 1379.96 186 -21% PBT % 19.95% 26.53% PAT # 870.94 117 1140.77 153 -24% PAT % 15.96% 21.93% #
Slide 15: Financials - Standalone: Profitability
Financials - Standalone Profitability FY 2021-22 FY 2020-21 PBIDT 23.25% 29.50% PBT 19.95% 26.53% PAT 15.96% 21.93% 15
Slide 16: Financials - Standalone: Business Characteristics
Financials - Standalone Business Characteristics FY 2021-22 FY 2020-21 Return on Capital Employed % (PBIT / Capital Employed) 17.95% 27.97% Return on Net Worth % (PAT / Net Worth) 15.77% 24.00% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.30 2.54 Capital Employed Turnover Ratio (To
Slide 17: Financials - Standalone: Growth
Financials - Standalone Growth FY 2021-22 FY 2020-21 Net Total Income 4.9% 17.4% Domestic Sales 19.7% 9.5% Export Sales -7.9% 26.7% PBIDT -17.4% 54.5% PBT -21.1% 75.8% Net Profit -23.7% 74.8% 17
Slide 18: Financials - Standalone Q1 FY23
Financials - Standalone Q1 FY23 Q1 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1488.09 192 1492.21 202 0% EBIDT 290.51 38 404.37 55 -28% EBIDT % 19.52% 27.10% PBT # 216.06 28 356.37 48 -39% PBT % 14.52% 23.88% PAT # 143.82 19 284.72 39 -49% PAT % 9.66% 19.08% # After forex gain of ` 3.22 Cr
Slide 19: Financials - Consolidated
Financials - Consolidated F.Y. 2021 - 22 F.Y. 2020 - 21 % Rs. Crs US$ Mn Rs. Crs US$ Mn Growth Total Income 5896.36 792 5482.83 737 8% EBIDT 1345.04 181 1565.89 210 -14% EBIDT % 22.81% 28.56% PBT # 1135.72 153 1388.98 187 -18% PBT % 19.26% 25.33% PAT # 884.08 119 1140.01 153 -22% PAT % 14.99% 20.79%
Slide 20: Financials - Consolidated: Business Characteristics
Financials - Consolidated Business Characteristics FY 2021-22 FY 2020-21 Return on Capital Employed % (PBIT / Capital Employed) 18.61% 28.24% Return on Net Worth % (PAT / Net Worth) 15.88% 24.17% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.16 2.38 Capital Employed Turnover Ratio (
Slide 21: Financials - Consolidated: Growth
Financials - Consolidated Growth FY 2021-22 FY 2020-21 Net Total Income 7.5% 16.3% Domestic Sales 22.7% 9.2% Export Sales -4.9% 24.1% PBIDT -14.1% 54.1% PBT -18.2% 86.0% Net Profit -22.4% 86.5% 21
Slide 22: Financials - Consolidated Q1 FY23
Financials - Consolidated Q1 FY23 Q1 FY22 % ` Crs US$ Mn ` Crs US$ Mn Growth Total Income 1607.85 208 1586.81 215 1% EBIDT 305.57 39 434.10 59 -30% EBIDT % 19.00% 27.36% PBT # 222.69 29 379.87 51 -41% PBT % 13.85% 23.94% PAT # 143.06 18 306.66 42 -53% PAT % 8.90% 19.33% # After forex gain of ` 3.46
Slide 23: Contribution of Therapeutic Groups
Financials - Standalone Contribution of Therapeutic Groups Domestic Exports Therapeutic Segment 2021 – 22 2020 – 21 2021 – 22 2020 – 21 Non Steroidal Anti-Inflammatory Drugs (NSAID) 49% 52% 21% 28% Cardiovasculars & Anti-Diabetics 17% 19% 25% 23% Anti-Bacterials 7% 6% 6% 5% Anti-Malarials 5% 4% 24%
Slide 24: Branded Formulations: Domestic
Branded Formulations Domestic 24
Slide 25: Branded Formulations - Domestic
Branded Formulations Domestic All India Rank IQVIA : 17th (MAT June’22). 24 Depots & 1 C&F agents. 17 Therapy Focused Marketing Divisions. Field Strength (PSR/ BA)– 5590 Over 4000 Wholesalers. 5 brands among top 300 brands (Zerodol-SP, Zerodol-P, HCQS, Zerodol TH & Folitrax). Market leaders in Rheum
Slide 26: Branded Formulations Domestic Sales
Branded Formulations Domestic Rs. 2508.27 Crs US $ 337 Mn Rs. 1981.67 Crs Rs. 1912.61 Crs US$ 266 Mn Rs. 1646.83 Crs US$ 270 Mn US$ 232 Mn Sales 2018-19 2019-20 2020-21 2021-22 26
Slide 27: Branded Formulations Future Growth Drivers
Branded Formulations Domestic Future Growth Drivers Clinical research as a tool to launch innovative combination formulations / NDDS. Strong Brand building with focused promotion. In licensing/ out licensing to build business in the promoted therapy. Portfolio optimization, strategies to identify ne
Slide 28: International Business
S£ipca A dose of life International Business
Slide 29: International Business
International Business Products of the company are now exported to over 100 countries across the globe. Recognized Star Trading House. 46% sales from exports. Field-force to promote brands in more than 35 countries of CIS, South East Asia, Middle East, Latin America and Africa. 29
Slide 30: International Business - Marketing Offices
International Business Marketing offices in Russia, Ukraine, Kazakhstan, Belarus , Vietnam, Philippines, Sri Lanka, Myanmar Kenya, Colombia, and Nigeria & Mexico (subsidiary company). Formulation dossiers for branded formulations registered in 55 countries. 30
Slide 31: International Business Sales
International Business Rs. 2717.19 Crs US$ 365 Mn Rs. 2502.69 Crs US $ 336 Mn Rs. 2143.75 Crs US$ 303 Mn Rs. 1730.84 Crs US$ 244 Mn Sales 2018-19 2019-20 2020-21 2021-22 31
Slide 32: Continent-wise Exports 2021-22
International Business Continent-wise Exports 2021 –22 (Rs. Crs) Bulk Drugs / % Continent Formulations Intermediates Total Contribution Europe 436.49 232.44 668.93 27% Africa 409.85 62.00 471.85 19% Americas 162.80 335.96 498.76 20% Asia 98.91 356.92 455.83 18% CIS 134.07 25.72 159.79 6% Australasia
Slide 33: International Formulations
International Formulations 33
Slide 34: International Formulations Sales
International Formulations Rs. 1597.19 Crs US$ 215 Mn Rs. 1486.74 Crs US $ 200 Mn Rs. 1221.55 Crs Rs. 1048.26 Crs US$ 172 Mn US$ 148 Mn Sales 2018-19 2019-20 2020-21 2021-22 34
Slide 35: International Branded Formulations
International Branded Formulations 35
Slide 36: International Branded Formulations Sales
International Branded Formulations Rs. 415.99 Crs US $ 56 Mn Rs. 403.42 Crs US$ 54 Mn Rs. 381.53 Crs US$ 54 Mn Rs. 360.94 Crs US$ 51 Mn Sales 2018-19 2019-20 2020-21 2021-22 36
Slide 37: International Branded Formulations Future Growth Drivers
International Branded Formulations Future Growth Drivers Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of new
Slide 38: International Generics
S£ipca A dose of life International Generics
Slide 39: International Generics Sales and Products
International Generics Sales Rs. 1193.77 Crs Products Products US$ 160 Mn Country Under Rs. 1070.75 Crs Registered Registration US $ 144 Mn Rs. 840.02 Crs US$ 119 Mn United Kingdom Rs. 687.32 Crs 83 14 / Europe US$ 97 Mn Australia / 73 1 New Zealand South Africa 46 17 2018-19 2019-20 2020-21 2021-22
Slide 40: Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Future G
Slide 41: International APIs
S£ipca dose of life International APIs
Slide 42: International APIs Sales
International APIs Rs. 1120.00 Crs Rs. 1015.95 Crs US$ 151 Mn US $ 136 Mn Rs. 922.20 Crs US$ 130 Mn Rs. 682.58 Crs US$ 96 Mn Sales 2018-19 2019-20 2020-21 2021-22 42
Slide 43: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 1 Atenolol a a a CEP a 2 Artemether a a 3 Artesunate a 4 Artesunate Sterile a 5 Amodiaquine Hcl a 6 Amlodipine Besylate a a 7 Allopurinol a a CEP a 8 Atovaquone a 9 Benzarone a 10 Benz
Slide 44: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM Cetrizine Hydrochloride (CZ5/ CZ6 16 Process) a CEP 17 Chloroquine Phosphate a a 18 Chlorthalidone a 19 Chlorthalidone (CT3/CT7 Process) a 20 Chlorthalidone (CT7 Process) a 21 Chlortha
Slide 45: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 31 Frusemide a a a CEP a 32 Frusemide (Vetirinary) a 33 Glimepiride a a a 34 Hydrochlorothiazide (Process I) a a a CEP a 35 Hydrochlorothiazide (Process II) a a 36 Hydrochlorothiazide
Slide 46: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 46 Mesalamine (MZ4 Process) a 47 Mesalazine a 48 Mesalazine (MZ4B Process) a 49 Metformin HCL a a 50 Metformin HCL (ML Process) a 51 Metformin HCL (ML2 Process) a 52 Metoclopramide HCl
Slide 47: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 61 Ondansetron Hydrochloride a a CEP a 62 Ondansetron Base a a a 63 Paroxetine Hcl CEP a 64 Primaquine Phosphate a a 65 Piperaquine Phosphate a 66 Probenecid a 67 Proguanil Hydrochlori
Slide 48: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 76 Ractopamine Hcl a a 77 Sodium Alendronate a a a 78 Telmisartan a 79 Telmisartan (WT3A Process) a 80 Torsemide a a 81 Tramadol Hydrochloride a Tramadol Hydrochloride (YT2 82 Process)
Slide 49: APIs - Drug Master Files
International APIs – Drug Master Files US- Canada- Japan - Sr. No. Name of the API FDA HPFB WHO PMDA Australia EDQM 91 Warfarin Sodium Clathrate a a 92 Warfarin Sodium CEP a 93 Zaltoprofen a Total 52 23 7 14 18 55 Note : Australia accept CEP issued by EDQM 49
Slide 50: APIs Future Growth Drivers
International APIs Future Growth Drivers Consolidate API business of Sartans across the globe. Long term strategic tie-ups with major South American/European formulators. Leverage the customer base of more than 1000 customers spread across 90 countries is well laid down platform to introduce Ipca ne
Slide 51: Research & Development: APIs & Formulations
Research & Development APIs & Formulations 51
Slide 52: R&D Spending
Research & Development APIs & Formulations R & D Spending Year Rs. Crs % to Sales 2017-18 118.10 3.73% 2018-19 89.35 2.50% 2019-20 101.04 2.35% 2020-21 126.67 2.49% 2021-22 141.46 2.65% 52
Slide 53: Research & Development
Research & Development APIs & Formulations Current scientist manpower of around 522. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Bio-tech / fermentati
Slide 54: Inception of Advanced Biotech Lab
Inception of Advanced Biotech Lab (Biosimilar R&D) Established “state of the art” R&D in 2015 Lashed with modern equipments and HTP devices Capable of In-house development from “Clone to Clinic” Scientific staff : 60 Products: Mammalian based “mAbs” Microbial based “Non-mAbs” 54
Slide 55: Biosimilar Pipelines
Biosimilar Pipelines Molecules: Anti-cancer and Anti-inflammatory mAbs Selected 5 Non-mAb Molecules for EU and USA Market 55
Slide 56: Thank you
Thank you No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited. This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in